GALMED PHARMACEUTICALS LTD. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
GALMED PHARMACEUTICALS LTD. (GLMD) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $113.00 thousand for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-31.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-03-31
- GALMED PHARMACEUTICALS LTD. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $13.00K.
- GALMED PHARMACEUTICALS LTD. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $87.00K, a 6.45% decline year-over-year.
- GALMED PHARMACEUTICALS LTD. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-06-30 was -$6.00K, a 130.00% decline year-over-year.
- GALMED PHARMACEUTICALS LTD. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-03-31 was $19.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $13.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-31 | $100.00K derived: sum of 2 quarters · filed 2026-03-31 | $94.00K derived: sum of 3 quarters · filed 2026-03-31 | $113.00K 20-F · filed 2026-03-31 |
| 2025-09-30 | $87.00K 6-K · filed 2025-11-26 | $81.00K derived: sum of 2 quarters · filed 2025-11-26 | $100.00K 6-K · filed 2025-11-26 | $26.00K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-06-30 | -$6.00K 6-K · filed 2025-08-28 | $13.00K 6-K · filed 2025-08-28 | -$61.00K derived: sum of 3 quarters · filed 2026-03-31 | $32.00K derived: sum of 4 quarters · filed 2026-03-31 |
| 2025-03-31 | $19.00K derived: 20-F 12 month − 3 quarters · filed 2026-03-31 | -$55.00K derived: sum of 2 quarters · filed 2026-03-31 | $38.00K derived: sum of 3 quarters · filed 2026-03-31 | $58.00K derived: sum of 4 quarters · filed 2026-03-31 |
| 2024-12-31 | -$74.00K derived: 20-F 12 month − 6-K 9 month · filed 2026-03-31 | $19.00K derived: sum of 2 quarters · filed 2026-03-31 | $39.00K derived: sum of 3 quarters · filed 2026-03-31 | $38.00K 20-F · filed 2026-03-31 |
| 2024-09-30 | $93.00K 6-K · filed 2025-11-26 | $113.00K derived: sum of 2 quarters · filed 2025-11-26 | $112.00K 6-K · filed 2025-11-26 | |
| 2024-06-30 | $20.00K 6-K · filed 2025-08-28 | $19.00K 6-K · filed 2025-08-28 | ||
| 2023-12-31 | $291.00K 20-F · filed 2026-03-31 | |||
| 2023-06-30 | -$17.00K 6-K · filed 2024-08-28 | $83.00K 6-K · filed 2024-08-28 | ||
| 2022-12-31 | -$574.00K 20-F · filed 2025-04-02 | |||
| 2022-06-30 | -$366.00K 6-K · filed 2023-08-09 | -$811.00K 6-K · filed 2023-08-09 | ||
| 2021-12-31 | -$443.00K 20-F · filed 2024-04-04 | |||
| 2021-06-30 | -$34.00K 6-K · filed 2022-08-04 | -$164.00K 6-K · filed 2022-08-04 | ||
| 2020-12-31 | $237.00K 20-F · filed 2023-03-29 | |||
| 2020-06-30 | $725.00K 6-K · filed 2021-08-05 | $463.00K 6-K · filed 2021-08-05 | ||
| 2019-12-31 | $46.00K 20-F · filed 2022-05-02 |